Ma, Jun
Chan, Jack Junjie http://orcid.org/0000-0002-7214-8368
Toh, Ching Han http://orcid.org/0009-0000-1673-7638
Yap, Yoon-Sim http://orcid.org/0000-0002-0347-5066
Funding for this research was provided by:
MOH | National Medical Research Council (CSAINV18nov-009)
Article History
Received: 6 April 2023
Accepted: 21 August 2023
First Online: 8 September 2023
Competing interests
: J.M.—travel, accommodations, expenses: AstraZeneca. J.J.C.—honoraria: AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Eisai, DKSH Singapore; Consulting or advisory role: Pfizer, Novartis, AstraZeneca, DKSH Singapore, Merck Sharp & Dohme, GlaxoSmithKline; Research funding: OncoQuest (institution), Bristol-Myers Squibb (institution); travel, accommodations, expenses: Novartis, Merck KGaA, DKSH Singapore, Roche, Pfizer. C.H.T.—none. Y.-S.Y.—honoraria: Novartis, Pfizer, Lilly/DKSH, AstraZeneca, Eisai, MSD, Specialized Therapeutics, Roche; research funding: Merck Sharp & Dohme; Travel, accommodations, expenses: DKSH, AstraZeneca.